Cloud-Based Rare Disease Family Registry Market Report 2026

The cloud-based rare disease family registry market size has grown rapidly in recent years. It will grow from $1.4 billion in 2025 to $1.65 billion in 2026 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to growth of rare disease research initiatives, increasing patient advocacy involvement, expansion of clinical trial networks, rising adoption of electronic data capture tools, need for centralized patient data systems.

The cloud-based rare disease family registry market size is expected to see rapid growth in the next few years. It will grow to $3.15 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing investments in orphan drug development, rising demand for real-world evidence generation, expansion of precision medicine research, growing use of ai-driven data analytics, increasing emphasis on patient-centric research models. Major trends in the forecast period include increasing adoption of cloud-based patient registries, rising use of digital platforms for rare disease research, growing integration of genomic and clinical data, expansion of global clinical trial recruitment tools, enhanced focus on secure data sharing.

The growing focus on precision medicine is expected to drive the expansion of the cloud-based rare disease family registry market. Precision medicine tailors treatment and prevention strategies to an individual’s genetic, environmental, and lifestyle factors. Its adoption is increasing due to advances in genomic sequencing, which allow healthcare providers to understand patients’ genetic profiles more accurately. Cloud-based rare disease family registries support precision medicine by collecting and centralizing detailed patient data, including genetic, clinical, and treatment information. For example, in February 2024, the Personalized Medicine Coalition reported that the US Food and Drug Administration approved 16 new personalized therapies for rare disease patients in 2023, up from six in 2022, with seven targeting cancer and three addressing other conditions. This growing focus on precision medicine is therefore fueling market growth.

Companies in the cloud-based rare disease family registry market are also innovating with technologies such as bilingual federated registries, which provide secure, multi-location platforms for patients, families, and researchers. These systems allow data to remain at local sites while supporting multiple languages and complying with regional consent and privacy regulations. For instance, in June 2025, the US-based National Organization for Rare Disorders (NORD) planned to launch two Canadian patient registries for PKU and MPS as part of the IAMRARE Program. Developed with Canadian patient advocacy groups, researchers, and clinicians, these registries comply with provincial consent requirements, enable cooperative real-time data collection and analysis, and support research, improved understanding of rare metabolic disorders, and clinical trial recruitment.

In May 2025, US-based equity firm Vora Ventures acquired Hive Networks Inc. for an undisclosed amount. This acquisition expands Hive Networks’ reach by leveraging its cloud-based AI-powered platform to enhance collaboration, data sharing, and patient outcomes in rare and chronic disease communities. Hive Networks provides a secure, cloud-based infrastructure for patients, families, clinicians, and researchers to share data, insights, and best practices, strengthening collaborative efforts in rare disease research and care.

Major companies operating in the cloud-based rare disease family registry market are Thermo Fisher Scientific Inc., IQVIA Holdings Inc., ICON plc, Syneos Health Inc., Parexel International Corp., Medidata Solutions Inc., FIGMD Inc., OM1 Inc., Mission Health Labs Inc., TREAT-NMD Global Registries Platform, Seqster PDM Inc., ArborMetrix Inc., OpenClinica LLC, Pulse Infoframe Inc., Oracle Healthcare Pvt. Ltd., QuesGen Systems Inc., FTD Disorders Registry, Castor LLC, Data Registry Services LLC, Fibrolamellar Registry, Rare Central.

North America was the largest region in the cloud-based rare disease family registry market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cloud-based rare disease family registry market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cloud-based rare disease family registry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cloud-based rare disease family registry market by increasing costs of imported servers, cybersecurity systems, storage hardware, and cloud infrastructure components. Research institutes and biotechnology firms in North America and Europe are most affected due to reliance on advanced imported IT equipment, while Asia-Pacific faces higher costs in expanding cloud-based research platforms. These tariffs are increasing implementation costs and slowing platform expansion. However, they are also encouraging domestic cloud infrastructure development, regional hosting services, and software-driven registry solutions that reduce hardware dependence.

The cloud-based rare disease family registry market research report is one of a series of new reports that provides cloud-based rare disease family registry market statistics, including cloud-based rare disease family registry industry global market size, regional shares, competitors with a cloud-based rare disease family registry market share, detailed cloud-based rare disease family registry market segments, market trends and opportunities, and any further data you may need to thrive in the cloud-based rare disease family registry industry. This cloud-based rare disease family registry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A cloud-based rare disease family registry is an online platform that securely collects, stores, and manages health and family information related to rare diseases. It enables patients, families, and healthcare professionals to share data from any location, supporting research, improving care, and facilitating clinical trial recruitment.

The key components of a cloud-based rare disease family registry include software and services. Software consists of programs, data, and instructions that enable computers or devices to perform specific tasks. The registry can be deployed through public, private, or hybrid cloud models. Its applications include patient data management, research, clinical trials, genetic data collection, and more. End-users include hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, patient advocacy groups, and other stakeholders.

The cloud-based rare disease family registry market consists of revenues earned by entities by providing services such as data hosting, data integration, data security, data sharing, data analytics, data storage, interoperability support, registry customization, patient engagement support, technical support, and training services, maintenance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cloud-based rare disease family registry market also includes sales of data storage devices, networking equipment, diagnostic kits, biometric devices, patient monitoring devices, data backup systems, security hardware, computing workstations, and mobile devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.